Imagene AI, a Miami-based firm developing AI-enabled digital pathology tools, secured $23 million in a Series B financing round led by Oracle's Larry Ellison. The company uses advanced foundation models trained on over 1.5 million biopsy images to guide precision medicine, from trial design to patient stratification. Imagene AI is expanding collaborations including a biomarker prediction panel with Tempus AI and partnerships with health systems to accelerate adoption of its platform in clinical trials and oncology.